ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO1006

Prevalence of Antihypertensive Use in CKD

Session Information

Category: CKD (Non-Dialysis)

  • 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention


  • Tangri, Navdeep, University of Manitoba, Winnipeg, Manitoba, Canada
  • Kushner, Pamela R., University of California Irvine, Irvine, California, United States
  • Barone, Salvatore, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, United States
  • Arnold, Matthew, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
  • Chen, Hungta (tony), BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, United States
  • Wittbrodt, Eric T., BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, United States

Treatment-resistant hypertension (TRH) is a comorbidity of concern in patients with chronic kidney disease (CKD) and elevates the risk of cardiovascular events. The aim of this analysis was to identify the prevalence of antihypertensive medication (AHM) use in patients with persistent TRH concurrent with CKD, overall and stratified by CKD stage.


The study cohort was comprised of adults with CKD in the US TriNetX database between 2008 and 2020. CKD index was defined as the second of two consecutive eGFR measurements <75 ml/min/m2 between 91-730 days apart or ICD-9/10 code of CKD or dialysis. Patients with >1 systolic blood pressure (SBP) >130 mm Hg within 6 months before or any time after index were included, and of these, TRH was defined as taking >3 AHM classes. The number of AHM prescribed 0 to >4 were described overall and by CKD stage. A sensitivity analysis using SBP >140 mm Hg was also performed.


In the cohort with CKD and SBP >130 mm Hg (N = 109,385), mean (SD) age was 64 (13) years, 57% were female, and 77% were White and 20% were Black. Median (IQR) SBP measurements was 3 (1,5). Proportion of patients with TRH was 18.6% overall, and by CKD stage was 13.8% (S1 and 2), 21.5% (S3), 35.7% (S4), and 37.5% (S5). These proportions were modestly increased in the sensitivity analysis.


In a large real-world cohort, TRH was detected in nearly 1 in 5 individuals with CKD, and no AHM use was observed in nearly half of CKD patients with elevated SBP. An opportunity clearly exists for improved management of TRH in order to avoid adverse clinical outcomes in this high-risk population.


  • Commercial Support – AstraZeneca